NASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis $23.42 +0.18 (+0.77%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About BridgeBio Pharma Stock (NASDAQ:BBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BridgeBio Pharma alerts:Sign Up Key Stats Today's Range$22.47▼$23.6550-Day Range$22.35▼$27.0952-Week Range$21.62▼$44.32Volume2.09 million shsAverage Volume1.85 million shsMarket Capitalization$4.43 billionP/E RatioN/ADividend YieldN/APrice Target$47.57Consensus RatingModerate Buy Company OverviewBridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Read More… 2024 Election Year Stocks: Uncover Hidden Gems! (Ad)In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. BridgeBio Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks92nd Percentile Overall ScoreBBIO MarketRank™: BridgeBio Pharma scored higher than 92% of companies evaluated by MarketBeat, and ranked 96th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for BridgeBio Pharma are expected to decrease in the coming year, from ($2.58) to ($3.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -9.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -9.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BridgeBio Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.71% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in BridgeBio Pharma has recently decreased by 3.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.31 Percentage of Shares Shorted11.71% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in BridgeBio Pharma has recently decreased by 3.26%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment-0.03 News SentimentBridgeBio Pharma has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for BridgeBio Pharma this week, compared to 7 articles on an average week.Search Interest17 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 143% compared to the previous 30 days.MarketBeat Follows4 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $150,056,923.00 in company stock.Percentage Held by Insiders24.66% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Pharma's insider trading history. Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Stock News HeadlinesInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells 4,156 Shares of StockNovember 21 at 8:35 AM | insidertrades.comUS FDA approves BridgeBio's drug for rare heart conditionNovember 22 at 7:25 PM | reuters.comTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.November 23, 2024 | Weiss Ratings (Ad)Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM PatientsNovember 22 at 7:11 PM | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $47.57 Consensus Target Price from BrokeragesNovember 22 at 5:39 AM | americanbankingnews.comBridgeBio Pharma call volume above normal and directionally bullishNovember 21 at 10:20 PM | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on BridgeBio Pharma (BBIO)November 21 at 5:20 PM | markets.businessinsider.comBridgeBio Pharma’s Promising Developments and Undervalued Market Position: A Buy Rating AnalysisNovember 20 at 5:14 AM | markets.businessinsider.comSee More Headlines BBIO Stock Analysis - Frequently Asked Questions How have BBIO shares performed this year? BridgeBio Pharma's stock was trading at $40.37 at the start of the year. Since then, BBIO shares have decreased by 42.0% and is now trading at $23.42. View the best growth stocks for 2024 here. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) issued its quarterly earnings results on Thursday, August, 1st. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.61. The firm's quarterly revenue was up 32.1% compared to the same quarter last year. When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $225 million in an IPO on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. Who are BridgeBio Pharma's major shareholders? Top institutional investors of BridgeBio Pharma include Janus Henderson Group PLC (2.55%), Frazier Life Sciences Management L.P. (1.99%), Geode Capital Management LLC (1.81%) and The Manufacturers Life Insurance Company (0.81%). Insiders that own company stock include Genetic Disorder LP Kkr, Global Investors Lp Viking, Neil Kumar, Frank Mccormick, Brian C Stephenson, Randal W Scott, Hannah Valantine, Ronald J Daniels and Douglas A Dachille. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings8/01/2024Today11/22/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BBIO CUSIPN/A CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$47.57 High Stock Price Target$70.00 Low Stock Price Target$37.00 Potential Upside/Downside+103.1%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-643,200,000.00 Net Margins-201.53% Pretax Margin-204.94% Return on EquityN/A Return on Assets-74.34% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio3.19 Sales & Book Value Annual Sales$217.77 million Price / Sales20.33 Cash FlowN/A Price / Cash FlowN/A Book Value($6.45) per share Price / Book-3.63Miscellaneous Outstanding Shares188,990,000Free Float142,385,000Market Cap$4.43 billion OptionableOptionable Beta1.09 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:BBIO) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.